Nebius stock jumps nearly 10% in regular trading as AI-cloud names catch a bid

Nebius stock jumps nearly 10% in regular trading as AI-cloud names catch a bid

New York, Jan 12, 2026, 15:05 ET — Regular session

  • Nebius Group N.V. shares climbed roughly 10% on Monday, pushing further on a tech-driven rally.
  • Traders zeroed in on Nebius’ plan to roll out NVIDIA’s next-gen Rubin platform in 2026.
  • Investors await new capacity and product updates, with a technical webinar scheduled for Jan. 29.

Nebius Group N.V. shares surged close to 10% Monday afternoon, riding the tailwind from a tech sector rally as investors shifted focus back to AI infrastructure names.

This shift is significant since Nebius remains a modest public player in the market for premium graphics chips and data centers—the backbone supporting chatbots and various AI applications. When tech risk appetite rises, stocks like Nebius can experience sharp swings.

It comes as investors scramble to figure out who will snag early access to NVIDIA’s upcoming AI hardware—and who can actually convert that edge into paying clients. That uncertainty has loomed over the “AI cloud” trade since late 2025.

Nebius shares climbed 9.8% to $107.55 in afternoon trading. The stock hit a high of $107.98 and dipped to $96.32 earlier, after closing at $97.93 on Friday, according to market data.

On Jan. 5, the company announced plans to roll out NVIDIA’s Rubin accelerated computing platform via its Nebius AI Cloud and Token Factory product starting in the second half of 2026. Token Factory focuses on “inference,” meaning it runs trained AI models to generate outputs, according to the company. Nebius

Arkady Volozh, founder and CEO, said Nebius plans to be “one of the first on the market” to offer NVIDIA’s Vera Rubin GPUs. The company is targeting customers looking to build “agentic” AI — systems that can plan and act with minimal human input. Businesswire

Tech stocks edged slightly higher. Nvidia rose roughly 1.0%, the Invesco QQQ Trust, tracking the Nasdaq-100, added about 0.3%, and the SPDR S&P 500 ETF climbed close to 0.2%.

NVIDIA confirmed that Rubin is now in full production, with Rubin-based products set to hit partner platforms in the second half of 2026. The company named Nebius as one of the early cloud partners planning to roll out Rubin-based instances next year, alongside bigger players and AI-focused competitors like CoreWeave. Nvidia

Investors are zeroing in on near-term capacity signals—the less flashy side that often drives results. Nebius plans a technical webinar on its Nebius AI Cloud 3.1 update, with a live Q&A, set for Jan. 29. Nebius

The road ahead isn’t smooth. Rubin won’t be available for months, and even before new hardware hits the market, the stock’s been swinging wildly day to day. High short interest could push it either way. MarketBeat data shows 33.1 million Nebius shares were sold short as of Dec. 15, roughly 13% of the public float. Marketbeat

Traders are zeroing in on the Jan. 29 webinar, expecting concrete updates on capacity, customer uptake, and timelines — details that could either cement the recent rally or trigger a pullback.

Stock Market Today

  • Kevin Warsh Named Fed Chair: A Different Approach from Hawks and Keynesians
    February 1, 2026, 9:41 PM EST. President Trump has appointed Kevin Warsh as the new Federal Reserve Chair, surprising market expectations that favored a more dovish candidate. Warsh, known for his past criticism of the Fed's inflation policies and skepticism toward quantitative easing, contrasts the looser monetary policies of the Keynesian era. Despite being labeled a 'hawk', his approach centers on encouraging productivity and private-sector credit over financial engineering. Warsh aligns with Treasury Secretary Scott Bessent's call for an AI-driven productivity boom and a flexible interest rate strategy akin to Alan Greenspan's during the 1990s internet revolution. Markets reacted sharply, notably punishing precious metals like gold and silver amid fears of a hawkish Fed stance.
Figure Technology Solutions stock drops nearly 10% after FIGR posts preliminary Q4 loan data
Previous Story

Figure Technology Solutions stock drops nearly 10% after FIGR posts preliminary Q4 loan data

Summit Therapeutics stock tumbles as FDA filing for ivonescimab hits tape, GSK trial tie-up follows
Next Story

Summit Therapeutics stock tumbles as FDA filing for ivonescimab hits tape, GSK trial tie-up follows

Go toTop